Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9NUU6
UPID:
OTULL_HUMAN
Alternative names:
-
Alternative UPACC:
Q9NUU6; Q53H50; Q9H037
Background:
Inactive ubiquitin thioesterase OTULINL, encoded by the gene with accession number Q9NUU6, is characterized by its lack of deubiquitinase activity. This protein plays a unique role in cellular processes by potentially regulating ubiquitination, a critical post-translational modification involved in signaling, DNA repair, and proteasomal degradation.
Therapeutic significance:
Understanding the role of Inactive ubiquitin thioesterase OTULINL could open doors to potential therapeutic strategies. Its unique position in cellular pathways makes it a candidate for further research to uncover novel drug targets.